secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001193125-23-144226
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica Q1 net loss $19.3M ($23.43/sh); cash $34.2M; Nasdaq delisted
------------------------------------------------------------------------

- Net loss $19.3M ($23.43 diluted EPS); operating expenses $22.3M incl. $16.2M one-time Graybug merger costs.
- Cash, equivalents and short-term investments $34.2M as of March 31; expects runway into H2 2024.
- CARPO Phase 2b trial: IDMC reviewed first 90 pts, recommended continue; expects topline Q1 2024.
- Stock suspended from Nasdaq March 30; now trading on OTCQB, working to relist.
- Merger with Graybug closed March 20; CalciMedica equityholders own ~72%, Graybug ~28%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312523144226/0001193125-23-144226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312523144226/d463877d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-144226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer